Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.15
Views: 1747
Rating:

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Prof Gnant presents, at a press conference at SABCS 2015, results from the phase III ABCSG-18 clinical trial.

The results showed that adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor-positive breast cancer.

Read the news article here for more.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation